CACletus A. Arciero

Cletus A. Arciero

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Cletus A. Arciero has a total of 57 co-authors. Here are the top co-authors by number of shared publications:

  • Theresa Gillespie

    Division of Surgical Oncology, Department of Surgery Emory University School of Medicine Atlanta Georgia USA

    4 shared publications
  • Yuan Liu

    Division of Surgical Oncology, Department of Surgery, Winship Cancer Institute Emory University Atlanta Georgia USA

    4 shared publications
  • Preeti D. Subhedar

    Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA

    3 shared publications
  • Feifei Geng

    Department of Biostatistics and Bioinformatics, Rollins School of Public Health Emory University Atlanta Georgia USA

    2 shared publications
  • Limin Peng

    Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA

    2 shared publications
  • Mylin A. Torres

    Glenn Family Breast Center, Winship Cancer Institute, Atlanta, GA, USA

    2 shared publications

Latest Publications

  • Top advances of the year: Breast cancer

    by Heather Gatcombe, Demetria Smith Graziani, Tyler Kristoff, Cletus Arciero, Kevin Kalinsky

    Clinically impactful data from medical oncology, radiation oncology, and surgical oncology from this year are highlighted.

  • Patterns of completion axillary dissection for patients with cT1‐2N0 breast cancer undergoing total mastectomy with positive sentinel lymph nodes

    by Lara Schwieger, Lauren M. Postlewait, Preeti D. Subhedar, Feifei Geng, Yuan Liu, Theresa Gillespie, Cletus A. Arciero

    Background and Objectives: The ACOSOGZ0011 trial found that overall survival (OS) for patients with 1–2 positive nodes undergoing sentinel lymph node biopsy‐alone (SLNB) was noninferior to completion axillary lymph node dissection (ALND), but excluded patients undergoing mastectomy. Our study examined patterns of ALND and its relationship with OS for SLNB‐positive patients undergoing mastectomy.Methods: The National Cancer Database was queried (2010–2017) for patients with cT1‐2N0 breast cancer undergoing mastectomy with positive sentinel lymph nodes. Clinical data were compared.Results: Of 20 001 patients, 11 574 (57.9%) underwent SLNB + ALND, and 8427 (42.1%) had SLNB‐alone. The SLNB + ALND group had more positive nodes (mean 2.6 vs. 1.3, p < 0.001) and more frequently received nodal radiation (33.4% vs. 28.9%, p < 0.001). Patients diagnosed in later years were less likely to undergo ALND (2010: reference; 2017: odds ratio: 0.29, 95% confidence interval [CI]: 0.25–0.33, p < 0.001). ALND (hazard ratio [HR]: 0.97, 95% CI: 0.89–1.06, p = 0.49) and nodal radiation (HR: 0.92, 95% CI: 0.83–1.02, p = 1.06) were not independently associated with OS. Propensity‐score matched 5‐year OS was similar (SLNB + ALND: 90.9% vs. SLNB‐alone: 90.3%, p = 0.65).Conclusion: For patients undergoing mastectomy for cT1‐2N0 breast cancer with positive SLNB, SLNB‐alone was common and increased over time. Axillary radiation was not routinely delivered in the SLNB‐alone group. Completion ALND and nodal radiation were not associated with improved survival.


  • Outcomes of the same‐day discharge following mastectomy before, during and after COVID‐19 pandemic

    by Yuliya Olimpiadi, Alison R. Goldenberg, Lauren Postlewait, Theresa Gillespie, Cletus Arciero, Toncred Styblo, Yicun Cao, Jeffrey M. Switchenko, Monica Rizzo

    Background and Objectives: The majority of patients undergoing mastectomy before the COVID‐19 pandemic were admitted for 23‐h observation to the hospital. Indications for observation included drain care education, pain control and observation for possible early surgical complications. This study compared the rates of outpatient mastectomy before, during, and after the COVID‐19 pandemic and indirectly evaluated the safety of same‐day discharge.Methods: We retrospectively analyzed patients undergoing mastectomy using Current Procedural Terminology code 19303.Results: A total of 357 patients were included: 113 were treated pre‐COVID‐19, 82 patients during COVID‐19 and 162 post‐COVID‐19. The rate of outpatient mastectomies tripled during the pandemic from 17% to 51% (p < 0.001); after the pandemic remain high at 48%. The rate of bilateral mastectomies decreased during the pandemic to 30% from 48% prepandemic (p = 0.015). Pectoralis muscle block utilization increased during the COVID‐19 period from 36% to 59% (p = 0.002). No difference in complication rates, including surgical site infections, hematomas, and readmissions, pre and during COVID.Conclusions: The rate of outpatient mastectomy increased during the COVID‐19 pandemic. During this timeframe, perioperative complications did not increase, suggesting the safety of this practice.After the pandemic, the rate of outpatient mastectomy continued to be significantly higher than pre‐COVID.


  • The Landmark Series—Addressing Disparities in Breast Cancer Screening: New Recommendations for Black Women

    by Oluwadamilola M. Fayanju, Christine E. Edmonds, Sylvia A. Reyes, Cletus Arciero, Vivian J. Bea, Angelena Crown, Kathie-Ann Joseph

    Randomized, clinical trials have established the efficacy of screening mammography in improving survival from breast cancer for women through detection of


  • Triple‐negative apocrine carcinoma: A rare pathologic subtype with a better prognosis than other triple‐negative breast cancers

    by Cletus A. Arciero, Albert H. Diehl, Yuan Liu, Qin Sun, Theresa Gillespie, Xiaoxian Li, Preeti Subhedar

    Background and Methods: Apocrine adenocarcinoma is a rare subtype of breast cancer. We sought to compare the characteristics and survival of patients diagnosed with triple‐negative apocrine adenocarcinoma to those of patients diagnosed with triple‐negative invasive ductal carcinoma. Utilizing data from the National Cancer Database between 2004 and 2013, 70 524 eligible female patients with triple‐negative breast cancer were identified including 566 patients with apocrine adenocarcinomas and 69 958 patients with invasive ductal carcinoma. Descriptive statistics for each variable were reported. A comparison of each covariate between the study cohorts was assessed in univariate and multivariate analysis. Cox proportional models were used to calculate hazard ratios. Additionally, the propensity score matching method was implemented to reduce treatment selection bias.Results: Patients with triple‐negative apocrine tumors were more likely to be older, Caucasian, and have smaller, moderately to well‐differentiated tumors. Multivariable analysis noted a significantly improved survival for patients with triple‐negative apocrine carcinoma (TNAC) vs triple‐negative invasive ductal carcinoma (TNBC) (hazard ratio [HR] 0.65 [95% confidence interval [CI] [0.53‐0.81], P = 0 < .001). Propensity score matching analysis confirmed a significant difference in overall survival for patients with TNAC in comparison to TNBC (HR 0.79 [95% CI [0.63‐1.00], P = .05).Discussion: Triple‐negative apocrine adenocarcinomas have a modestly improved long‐term survival when compared with triple‐negative invasive ductal cancers.


  • Time from Completion of Neo‐adjuvant Chemotherapy to Surgery: Effects on Outcomes in Breast Cancer Patients

    by Cletus Arciero, Karen Buhariwalla, Yuan Liu, Mylin A. Torres, Preeti Subhedar

    There is no consensus on the ideal time interval between the completion of neo‐adjuvant chemotherapy (NAC) and definitive surgery for patients with breast cancer. This study sought to determine the ideal time interval from completion of systemic therapy to surgery in an attempt to define a best practice. A retrospective analysis of all patients undergoing NAC for Stage I‐III breast cancer from 1998‐2010 was undertaken. Analysis of all demographic and clinical information was performed, with emphasis on interval from completion of systemic therapy to definitive surgical management. Three hundred and eighty eight patients met the inclusion criteria with a median age of 50 (61.9% white, 33.8% black and 4.3% other). Overall, 2.8% of patients were Stage I, 57.2% Stage II and 40% Stage III. Median follow‐up was 85 months. Pathologic response to systemic therapy was complete in 20.6%, partial in 67.8% and no response or progression in 11.6%; responders (pCR or pPR) were noted to have significantly improved Disease free survival (DFS) and Overall survival (OS). Patients undergoing surgical intervention 4‐6 weeks after completion of NAC were noted to have a trend towards improved DFS and OS on multivariable analysis. These findings were also observed in the nonlinear relationship between survival risk and surgery time window using martingale residual plots. Timing of surgical intervention following the receipt of NAC may not appear to affect DFS or OS.


  • ER+/HER2+ Breast Cancer Has Different Metastatic Patterns and Better Survival Than ER−/HER2+ Breast Cancer

    by Cletus A. Arciero, Yi Guo, Renjian Jiang, Madhusmita Behera, Ruth O’rEgan, Limin Peng, Xiaoxian Li


  • Surgery and survival in patients with stage IV breast cancer

    by Cletus Arciero, Yuan Liu, Theresa Gillespie, Preeti Subhedar

    Background Retrospective studies have shown some improvement in survival for patients receiving surgical management of the intact primary tumor in patients with presenting with Stage IV disease, while prospective studies have revealed mixed results. Methods An examination of the NCDB from 2004‐2013 was undertaken to examine factors related to the utilization of surgery and overall survival in patients with de novo Stage IV disease. Univariate and multivariable analyses were conducted to determine factors related to survival. Propensity score matching method was implemented to balance patients' baseline characteristics. Results A total of 11 694 patients with Stage IV breast cancer at diagnosis met inclusion criteria. Surgical intervention occurred in 5202 patients (44.5%), with the use of surgery decreasing throughout the study period (53.6% surgery 2004‐2006; 31.8% surgery 2011‐2013). Selection for surgical intervention was associated with small tumors (T1) and a higher nodal burden (N2/3). Uninsured patients, those treated at academic centers, those treated in the Northeast, and those with hormone receptor positive tumors were less likely to undergo surgery. Surgery was independently associated with a better overall survival. Propensity score matching revealed a persistent survival advantage for surgical patients receiving surgery, regardless of the receipt of systemic therapy. Conclusions Surgery on the intact primary tumor for patients presenting with de novo Stage IV breast cancer is associated with improved overall survival. Surgical resection in patients with Stage IV breast cancer should be considered for well‐selected patients as a part of multimodality therapy.


    • 1 August 2018
      • Vol. 32  (8) , 392-396

    Multidisciplinary Approaches to Chest Wall Recurrences of Breast Cancer

    by Cletus Arciero, Peter Thompson, Jane Lowe Meisel, Caitlin E. Taylor, Mylin A. Torres, William C. Wood

    The management of postmastectomy chest wall recurrences of breast cancer has long challenged clinicians. A tissue diagnosis combined with proper imaging and staging of patients to ensure the disease is localized are the first steps in management. Multimodal therapy offers patients the best chances of cure. In properly selected patients, complete surgical resection to negative margins, including full-thickness chest wall resection when required, followed by reconstruction that is well planned, can provide local control with very low surgical mortality and acceptable morbidity. Radiation therapy provides additional local control, while systemic therapy is an adjunct that prolongs survival in many cases. Multidisciplinary care combined with careful patient selection are the keys to successful chest wall resection for locally recurrent breast cancer after mastectomy.